Alcon (ALC)
(Real Time Quote from BATS)
$94.64 USD
+0.23 (0.24%)
Updated Sep 6, 2024 03:48 PM ET
After-Market: $94.70 +0.06 (0.06%) 4:14 PM ET
4-Sell of 5 4
C Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.64 USD
+0.23 (0.24%)
Updated Sep 6, 2024 03:48 PM ET
After-Market: $94.70 +0.06 (0.06%) 4:14 PM ET
4-Sell of 5 4
C Value C Growth B Momentum C VGM
Zacks News
Paramount Global (PARA) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Paramount Global's (PARA) Q2 performance is expected to have been aided by growth in viewership, driven by strength in streaming services, including Paramount+ amid tepid advertiser demand.
Factors to Note Ahead of Atlassian's (TEAM) Q4 Earnings
by Zacks Equity Research
Atlassian's (TEAM) Q4 results are likely to reflect the rising demand for cloud solutions and the massive digitalization of work by organizations.
Twilio (TWLO) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Twilio's (TWLO) Q2 revenues are expected to have benefited from the accelerated digital transformation and recent acquisitions, while the elevated spending on product and market expansions might have weighed on earnings.
What's in the Offing for Amdocs (DOX) This Earnings Season?
by Zacks Equity Research
The increased demand for its cloud-managed services and continuous deal wins from major telecom companies are likely to have aided Amdocs' (DOX) third-quarter performance.
What's in the Offing for Cloudflare (NET) This Earnings Season?
by Zacks Equity Research
Cloudflare's (NET) Q2 performance is likely to have witnessed the solid demand for security solutions and the benefits of its recurring subscription-based business model and diversified customer base.
Electronic Arts (EA) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Electronic Arts' (EA) first-quarter fiscal 2023 results are expected to reflect steady demand for its digital and live services. However, the lack of major game releases might have dented profits.
Match Group (MTCH) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Match Group's (MTCH) second-quarter 2022 earnings are expected to have benefited from the continued momentum in Tinder and solid performances of other apps like Hinge, Plenty Of Fish and OkCupid.
Fortinet (FTNT) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Fortinet's (FTNT) second-quarter results are likely to reflect benefits from increased demand for IT security along with the strong adoption of its Fortinet Security Fabric, cloud and SD-WAN offerings.
DXC Technology (DXC) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
DXC Technology's (DXC) first-quarter fiscal 2023 performance is likely to have been negatively impacted by the business operation closure in Russia, the strong U.S. dollar and divestitures.
Paycom (PAYC) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Paycom's (PAYC) Q2 results are likely to have benefited from new client additions, business wins & market share gains. However, pandemic disruptions might impact its client headcount.
Neogen (NEOG) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Neogen (NEOG) delivers better-than-expected results for the fiscal fourth quarter, with robust segmental performance driving the top line.
Henry Schein (HSIC) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) Q2 performance will likely reflect continued strength in its dental and medical businesses.
IDEXX (IDXX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
IDEXX's (IDXX) Q2 performance will likely benefit from strong sales from the CAG Diagnostics and Water businesses.
Centene (CNC) Gears Up for Q2 Earnings: What Lies Ahead?
by Zacks Equity Research
Centene's (CNC) second-quarter results are likely to reflect growth in premiums.
Teladoc Health (TDOC) Gears Up for Q2 Earnings: What Lies Ahead?
by Zacks Equity Research
Teladoc Health's (TDOC) second-quarter results are likely to reflect growth in Subscription Access Fees.
Edwards Lifesciences (EW) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Edwards Lifesciences' (EW) Q2 performance will likely reflect the continued adoption of the RESILIA tissue valves and enhanced sales of the HemoSphere platform.
Exact Sciences (EXAS) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Exact Sciences' (EXAS) Q2 performance will likely reflect the benefit from continued adoption of the Oncotype DX breast test and robust Cologuard screening revenues.
Charles River (CRL) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
The broad-based demand and meaningful price increases in the RMS business, particularly in North America and China, are expected to have contributed to Charles River's (CRL) Q2 top line.
STERIS (STE) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) Key Surgical and Cantel Medical businesses make significant contributions to consumable revenues within the Healthcare arm in Q1.
Factors to Note Ahead of Humana (HUM) Q2 Earnings Release
by Zacks Equity Research
Humana's (HUM) second-quarter results are likely to reflect higher premiums from the Retail segment and overall membership growth, partly offset by elevated technology-linked investments.
Here's Why Alcon (ALC) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Alcon (ALC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Bio-Rad's (BIO) Clinical Diagnostics segment is expected to report growth in Q2, driven by its focus on laboratory workflow productivity, quality control, and new opportunities in molecular diagnostics.
Zimmer Biomet (ZBH) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet's (ZBH) S.E.T. arm is expected to deliver strong results on the back of the company's focus on sports and extremities, especially upper extremities, trauma and CMFT.
Lantheus (LNTH) to Report Q2 Results: What's in the Cards?
by Zacks Equity Research
Lantheus' (LNTH) Q2 performance is likely to gain from the continued uptake of PYLARIFY and DEFINITY.
Quest Diagnostics (DGX) Tops Q2 Earnings Estimates, Ups View
by Zacks Equity Research
Banking on consistent improvement in the company's Base business, Quest Diagnostics (DGX) raises its full-year 2022 guidance.